Deal Corner
January 01, 2000
Sequoia Capital India's investment of Rs. 1 billion in GVK Biosciences Private Limited

DEAL BRIEF

Sequoia Capital India invested Rs. 1 billion in GVK Biosciences Private Limited (GVK BIO), the Hyderabad based leading contract research organization which specializes in pharma and biotech research in the field of medicinal chemistry, informatics, clinical pharmacology and biology . Sequoia Capital India's investment will further empower GVK BIO in expanding its capacity in drug discovery services and providing new services in pre-clinical and clinical space.

OUR ROLE

We, at Nishith Desai Associates, acted as legal counsel for Sequoia Capital India in this investment.

Disclaimer

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

We expressly clarify that this communication is not a solicitation or an invitation of any sort whatsoever from Nishith Desai Associates or any of its members to create an attorney-client relationship. This communication is not intended to be a source of advertising and the recipient should always seek the advice of competent counsel licensed to practice in the recipient's country/state.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

NDA Connect

Connect with us at events, 
conferences and seminars.

Deal Corner

January 01, 2000

Sequoia Capital India's investment of Rs. 1 billion in GVK Biosciences Private Limited

DEAL BRIEF

Sequoia Capital India invested Rs. 1 billion in GVK Biosciences Private Limited (GVK BIO), the Hyderabad based leading contract research organization which specializes in pharma and biotech research in the field of medicinal chemistry, informatics, clinical pharmacology and biology . Sequoia Capital India's investment will further empower GVK BIO in expanding its capacity in drug discovery services and providing new services in pre-clinical and clinical space.

OUR ROLE

We, at Nishith Desai Associates, acted as legal counsel for Sequoia Capital India in this investment.

Disclaimer

We expressly clarify that this communication is not a solicitation or an invitation of any sort whatsoever from Nishith Desai Associates or any of its members to create an attorney-client relationship. This communication is not intended to be a source of advertising and the recipient should always seek the advice of competent counsel licensed to practice in the recipient's country/state.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

NDA Connect

Connect with us at events, 
conferences and seminars.